82 Recruiting Studies Using Bortezomib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Bortezomib
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Adult T Acute Lymphoblastic Leukemia
View Study & Checklist ➔Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Multiple Myeloma
View Study & Checklist ➔2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Multiple Myeloma
View Study & Checklist ➔A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
📍 Alaska Breast Care and Surgery LLC — Anchorage, Alaska
Lymphoma
View Study & Checklist ➔Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Univ of Colorado Cancer Center /ID# 167331 — Aurora, Colorado
Multiple Myeloma
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
Multiple Myeloma
View Study & Checklist ➔Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
📍 UCSF — San Francisco, California
Multiple Myeloma
View Study & Checklist ➔Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
📍 City of Hope — Duarte, California
Amyloidosis
View Study & Checklist ➔Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alaska Oncology and Hematology LLC — Anchorage, Alaska
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔DARA RVD For High Risk SMM
📍 Stamford Hospital — Stamford, Connecticut
High-risk Smoldering Multiple Myeloma
View Study & Checklist ➔A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
📍 UCSF Fresno — Clovis, California
Multiple Myeloma
View Study & Checklist ➔Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Plasma Cell Myeloma
View Study & Checklist ➔Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
📍 University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Multiple Myeloma
View Study & Checklist ➔Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
📍 University of California — Orange, California
AL Amyloidosis
View Study & Checklist ➔Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
Waldenstrom's Macroglobulinemia
View Study & Checklist ➔Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
Solid Tumor
View Study & Checklist ➔Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Multiple Myeloma
View Study & Checklist ➔A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
📍 University Of California San Diego — San Diego, California
Multiple Myeloma
View Study & Checklist ➔Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
📍 Providence Alaska Medical Center — Anchorage, Alaska
DS Stage I Multiple Myeloma
View Study & Checklist ➔Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
📍 GSK Investigational Site — Westwood, Kansas
Multiple Myeloma
View Study & Checklist ➔A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
📍 City of Hope — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
📍 University of Miami — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
📍 Los Angeles County-USC Medical Center — Los Angeles, California
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
📍 Alaska Oncology and Hematology LLC — Anchorage, Alaska
Myeloma Multiple
View Study & Checklist ➔A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
📍 Lucile Packard Children's Hospital Stanford University — Palo Alto, California
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
📍 Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
📍 University of Arkansas — Little Rock, Arkansas
Multiple Myeloma
View Study & Checklist ➔Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Yuma, Arizona
Multiple Myeloma
View Study & Checklist ➔Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
📍 Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
📍 Children's Hospital Los Angeles — Los Angeles, California
Acute Lymphoblastic Leukemia
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Plasma Cell Myeloma
View Study & Checklist ➔Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
📍 Mount Sinai Hospital — New York, New York
Mantle Cell Lymphoma
View Study & Checklist ➔Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoproliferative Disorder
View Study & Checklist ➔Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
📍 Local Institution - 035 — Hot Springs, Arkansas
Multiple Myeloma
View Study & Checklist ➔Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham - Main /ID# 261434 — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
📍 Local Institution - 102 — Scottsdale, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
📍 Investigational Site Number: 8400006 — Fort Myers, Florida
Plasma Cell Myeloma
View Study & Checklist ➔Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
📍 Gundersen Lutheran — La Crosse, Wisconsin
Multiple Myeloma
View Study & Checklist ➔A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Relapsed and/or Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
📍 Phoenix Children's Hospital — Phoenix, Arizona
Lymphoblastic Leukemia
View Study & Checklist ➔Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
📍 Masonic Cancer Center — Minneapolis, Minnesota
Acute Myeloid Leukemia
View Study & Checklist ➔A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
📍 Jupiter Medical Center/Anderson Family Cancer Institute — Jupiter, Florida
Multiple Myeloma
View Study & Checklist ➔Selinexor and Backbone Treatments of Multiple Myeloma Patients
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Plasma Cell Myeloma
View Study & Checklist ➔Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
📍 Research Site — Gilbert, Arizona
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
📍 Baylor University Medical Center, Baylor Charles A Sammons Cancer Center — Dallas, Texas
Breast Cancer
View Study & Checklist ➔Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
📍 Rady Children's Hospital — San Diego, California
T-cell Acute Lymphoblastic Leukemia
View Study & Checklist ➔Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Haematological Malignancy
View Study & Checklist ➔Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
📍 Cross Cancer Institute — Edmonton, Alberta
Multiple Myeloma
View Study & Checklist ➔A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
📍 Research Site — Gilbert, Arizona
Relapsed Refractory Multiple Myeloma
View Study & Checklist ➔HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
📍 Henry Ford hospital — Detroit, Michigan
Hematological Malignancy
View Study & Checklist ➔Two Schemes Response in Multiple Myeloma
📍 Hospital General de Mexico Dr. Eduardo Liceaga — Mexico City, Mexico City
Response, Acute Phase
View Study & Checklist ➔A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
📍 Memorial Sloan Kettering at Basking Ridge (Consent only) — Basking Ridge, New Jersey
Sickle Cell Disease
View Study & Checklist ➔A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
📍 Scripps Clinic Torrey Pines — La Jolla, California
Multiple Myeloma
View Study & Checklist ➔A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Myeloma
View Study & Checklist ➔A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
📍 Tufts Medical Center (Data Collection Only) — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Lymphoblastic Leukemia
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Los Alamitos, California
Multiple Myeloma
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
📍 GSK Investigational Site — Rochester, Minnesota
Amyloidosis
View Study & Checklist ➔Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
📍 Northwell Health — New Hyde Park, New York
Graft-versus-host Disease
View Study & Checklist ➔A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
📍 Local Institution - 0366 — Los Alamitos, California
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
📍 UT MD Anderson — Houston, Texas
T-cell Acute Lymphoblastic Leukemia
View Study & Checklist ➔MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
📍 Infirmary Cancer Care — Mobile, Alabama
Multiple Myeloma
View Study & Checklist ➔Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Multiple Myeloma
View Study & Checklist ➔Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Plasma Cell Myeloma
View Study & Checklist ➔Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
AL Amyloidosis
View Study & Checklist ➔